SCHEDULE 13G: Ayala Pharmaceuticals Discloses 9.99% Stake in OS Therapies

Ayala Pharmaceuticals, Inc. has filed a Schedule 13G, reporting a 9.99% beneficial ownership stake in OS Therapies Incorporated, holding 2,164,215 shares of common stock.

Summary

• Ayala Pharmaceuticals, Inc. has reported beneficial ownership of 2,164,215 shares of Common Stock in OS Therapies Incorporated.
• This stake represents 9.99% of OS Therapies' outstanding Common Stock, calculated based on 21,663,811 shares reported as outstanding as of March 28, 2025.
• The reported beneficial ownership excludes a warrant held by Ayala to purchase an additional 2,166,381 shares of Common Stock.
• It also excludes 444,041 additional shares of Common Stock that are issuable to Ayala, subject to obtaining approval from OS Therapies' stockholders.
• The warrant includes a beneficial ownership limitation, preventing its exercise if it would result in Ayala, together with its affiliates, beneficially owning more than 9.99% of the outstanding Common Stock immediately after exercise; this limitation can be changed by Ayala upon 61 days' notice to OS Therapies.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is inherently neutral. While a significant stake can be viewed positively, the filing itself does not contain promotional or negative language.

Positives

• Ayala Pharmaceuticals, Inc. has established a significant beneficial ownership stake of 9.99% in OS Therapies Incorporated, indicating a substantial investment or strategic interest.
• The potential for Ayala to acquire additional shares through a warrant (2,166,381 shares) and further consideration shares (444,041 shares) suggests a deeper, long-term relationship or strategic alignment, subject to certain conditions.

Negatives

• The beneficial ownership limitation of 9.99% on the warrant exercise restricts Ayala's immediate ability to increase its stake beyond this threshold without providing 61 days' notice to OS Therapies.
• The issuance of 444,041 additional shares is contingent upon obtaining approval from OS Therapies' stockholders, introducing an element of uncertainty regarding their full acquisition.

Risks

• **Beneficial Ownership Limitation**: Ayala's ability to increase its stake beyond 9.99% through the warrant is restricted by a beneficial ownership limitation, which requires 61 days' notice to the Issuer for a change.
• **Stockholder Approval Contingency**: The acquisition of 444,041 additional shares by Ayala is subject to obtaining approval from OS Therapies' stockholders, which is not guaranteed.

Future Outlook

Ayala Pharmaceuticals may increase its beneficial ownership in OS Therapies Incorporated through the exercise of a warrant for 2,166,381 shares and the issuance of an additional 444,041 shares, contingent upon OS Therapies' stockholder approval. The warrant exercise is subject to a 9.99% beneficial ownership limitation, which can be changed with 61 days' notice.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

This filing indicates a significant equity stake by one pharmaceutical company (Ayala) in another (OS Therapies). Such cross-company investments or ownership stakes are common in the biotechnology and pharmaceutical sectors, often stemming from strategic collaborations, mergers, acquisitions, or licensing agreements where equity is part of the consideration. It suggests a potential strategic alignment or a prior transaction between the two entities.

Related Party Transactions

• Ayala Pharmaceuticals' beneficial ownership in OS Therapies Incorporated, including warrants and additional consideration shares, suggests a prior strategic transaction or relationship between the two entities that resulted in this equity stake.

Stakeholder Impact

• **Shareholders of OS Therapies**: The significant stake held by Ayala Pharmaceuticals could influence future corporate decisions, strategic direction, or potential future transactions. The contingency of stockholder approval for additional shares directly impacts their voting rights.
• **Shareholders of Ayala Pharmaceuticals**: This filing confirms a substantial investment in OS Therapies, which could impact Ayala's asset valuation and strategic focus.

Next Steps

• OS Therapies' stockholders need to approve the issuance of 444,041 additional shares to Ayala.
• Ayala Pharmaceuticals may elect to change the 9.99% beneficial ownership limitation on the warrant exercise by providing 61 days' notice to OS Therapies.

Key Dates

Keywords

Ayala Pharmaceuticals, OS Therapies, Schedule 13G, Beneficial Ownership, Common Stock, Equity Stake, SEC Filing, Investment, Warrant, Shareholder